Apellis Pharmaceuticals (APLS) News Today → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free APLS Stock Alerts $40.75 -0.36 (-0.88%) (As of 05/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 3:47 PM | marketbeat.comFiduciary Trust Co Sells 22,600 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Fiduciary Trust Co cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,607 shares of the company's stock after seMay 30 at 6:16 AM | americanbankingnews.comZacks Research Equities Analysts Increase Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)May 29 at 6:48 AM | marketbeat.comFranklin Resources Inc. Purchases Shares of 229,790 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Franklin Resources Inc. purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 229,790 shares of the company's stock, valued at approximMay 29 at 6:24 AM | americanbankingnews.comZacks Research Comments on Apellis Pharmaceuticals, Inc.'s Q4 2025 Earnings (NASDAQ:APLS)May 29 at 6:20 AM | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post Q4 2025 Earnings of $0.42 Per Share, Zacks Research ForecastsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at Zacks Research reduced their Q4 2025 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued on Monday, May 27th. Zacks Research analyst R. Department now expects that the company will earn $0.42 pMay 28 at 10:12 PM | finance.yahoo.comThe Future of Cannabidiol (CBD) Pain Treatments, 2024: Commercial and Clinical Assessment with Analysis of Pipeline Development ActivitiesMay 28 at 12:10 PM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)May 28 at 12:10 PM | markets.businessinsider.comExpert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 AnalystsMay 28 at 8:16 AM | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Rating Reiterated by HC WainwrightMay 28 at 5:50 AM | marketbeat.comNorges Bank Buys New Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Norges Bank bought a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 946,213 shares of the company's stock, valued at approximately $56,640,000. NorgesMay 24, 2024 | globenewswire.comPositive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressMay 24, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $48.00 by Analysts at Wells Fargo & CompanyMay 24, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 5.9% on Analyst DowngradeMay 23, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 5.9% After Analyst DowngradeApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 5.9% After Analyst DowngradeMay 23, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $48.00 at Wells Fargo & CompanyWells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an "equal weight" rating on the stock in a research note on Thursday.May 18, 2024 | marketbeat.comGreat Lakes Advisors LLC Invests $12.46 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Great Lakes Advisors LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 208,163 shares of the company's stock, valued at approximately $12,461,000. Great Lakes AdvisMay 17, 2024 | marketbeat.comApellis Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.41) Per Share (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Wedbush upped their Q2 2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report issued on Wednesday, May 15th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($May 17, 2024 | marketbeat.comBNP Paribas Financial Markets Sells 68,867 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)BNP Paribas Financial Markets decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 167,488 shares of the company's stock after selling 68,867 shares durinMay 16, 2024 | marketbeat.comInvestors Buy High Volume of Call Options on Apellis Pharmaceuticals (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) saw some unusual options trading on Thursday. Investors purchased 40,472 call options on the company. This is an increase of 1,641% compared to the typical daily volume of 2,325 call options.May 16, 2024 | marketbeat.comWedbush Comments on Apellis Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush issued their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. Wedbush analyst L. Chico expects that the companMay 14, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4%Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%May 14, 2024 | marketbeat.comShort Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expands By 16.1%Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 12,390,000 shares, an increase of 16.1% from the April 15th total of 10,670,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is presently 8.4 days.May 14, 2024 | finance.yahoo.comApellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetMay 13, 2024 | seekingalpha.comApellis Pharmaceuticals Strives For Recovery Despite Syfovre SetbacksMay 11, 2024 | insidertrades.comPascal Deschatelets Sells 78,907 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockMay 10, 2024 | markets.businessinsider.comStrong Performance and Growth Potential Affirm Buy Rating for Apellis PharmaceuticalsMay 10, 2024 | marketbeat.comHC Wainwright Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst D. Tsao now expects that the cMay 9, 2024 | marketbeat.comWedbush Analysts Reduce Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush lowered their FY2026 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst L. Chico now expects that thMay 8, 2024 | markets.businessinsider.comApellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive PressuresMay 8, 2024 | msn.comApellis stock sell-off over Syfovre sales "overdone," says CitiMay 8, 2024 | markets.businessinsider.comIn-Depth Examination Of 14 Analyst Recommendations For Apellis PharmaceuticalsMay 8, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $60.00 Price Target at CitigroupCitigroup dropped their price target on Apellis Pharmaceuticals from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday.May 8, 2024 | marketbeat.comApellis Pharmaceuticals' (APLS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday.May 8, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Meets EstimatesApellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.54). The company had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business's revenue for the quarter was up 284.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.56) EPS.May 8, 2024 | finance.yahoo.comApellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 7, 2024 | finanznachrichten.deApellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | msn.comAPLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comApellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81May 7, 2024 | msn.comApellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04MMay 7, 2024 | globenewswire.comApellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comVictory Capital Management Inc. Has $36.89 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Victory Capital Management Inc. lessened its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 616,272 shares of theMay 6, 2024 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLCLisanti Capital Growth LLC trimmed its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 58.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,305 shares of the company's stock after selling 64,695May 6, 2024 | globenewswire.comApellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceMay 3, 2024 | marketbeat.comCalifornia Public Employees Retirement System Sells 38,011 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)California Public Employees Retirement System reduced its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 145,833 shares of the company'sMay 1, 2024 | globenewswire.comApellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingApril 30, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Sees Strong Trading VolumeApellis Pharmaceuticals (NASDAQ:APLS) Sees Large Volume IncreaseApril 30, 2024 | marketbeat.comApellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 18,182 call options on the company. This represents an increase of approximately 703% compared to the typical volume of 2,265 call options.April 30, 2024 | investing.comApellis Pharmaceuticals stock falls following Mizuho comments, price target cutApril 30, 2024 | benzinga.comA Closer Look at Apellis Pharmaceuticals's Options Market Dynamics Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Get out of dollars—get into America’s new money instead (Ad)Is America's New Money right for you? I can't say... but I do know it's 100% legal and available to everyone... although precious few know much about it. Everything you need to know is posted on our website here. APLS Media Mentions By Week APLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.430.82▲Average Medical News Sentiment APLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼198▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALXO News OMER News RIGL News MCRB News ALNY News TEVA News GMAB News RPRX News BGNE News BMRN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiden Nomination CANCELED?The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeGet out of dollars—get into America’s new money insteadStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.